Celcuity (CELC) | Financial Analysis & Statements
Celcuity Inc. Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
0
Operating Income
-49.2M
Net Income
-51.0M
EPS (Diluted)
$-0.97
Balance Sheet Metrics
Total Assets
466.6M
Total Liabilities
366.0M
Shareholders Equity
100.6M
Debt to Equity
3.64
Cash Flow Metrics
Operating Cash Flow
-35.5M
Free Cash Flow
-36.5M
Revenue & Profitability Trend
Celcuity Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses | |||||
| Research & Development | 145.0M | 104.2M | 60.6M | 35.3M | 25.8M |
| Selling, General & Administrative | 27.2M | 9.1M | 5.6M | 4.1M | 2.6M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 172.2M | 113.3M | 66.2M | 39.4M | 28.4M |
| Operating Income | -172.2M | -113.3M | -66.2M | -39.4M | -28.4M |
| Operating Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Non-Operating Items | |||||
| Interest Income | 12.3M | 11.8M | 7.8M | 1.1M | 13.3K |
| Interest Expense | 17.1M | 10.3M | 5.3M | 2.1M | 1.3M |
| Other Non-Operating Income | - | - | - | - | -263 |
| Pre-tax Income | -177.0M | -111.8M | -63.8M | -40.4M | -29.6M |
| Income Tax | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -177.0M | -111.8M | -63.8M | -40.4M | -29.6M |
| Net Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Key Metrics | |||||
| EBITDA | -159.7M | -101.4M | -58.3M | -38.1M | -28.0M |
| EPS (Basic) | $-3.79 | $-2.83 | $-2.69 | $-2.64 | $-2.21 |
| EPS (Diluted) | $-3.79 | $-2.83 | $-2.69 | $-2.64 | $-2.21 |
| Basic Shares Outstanding | 46757691 | 39449393 | 23679472 | 15418543 | 13382553 |
| Diluted Shares Outstanding | 46757691 | 39449393 | 23679472 | 15418543 | 13382553 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Celcuity Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 165.7M | 22.5M | 30.7M | 24.6M | 84.3M |
| Short-term Investments | 275.8M | 212.6M | 149.9M | 144.0M | 0 |
| Accounts Receivable | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Other Current Assets | 5.3M | 841.3K | 281.4K | 351.1K | - |
| Total Current Assets | 465.7M | 244.6M | 190.6M | 175.2M | 85.4M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 51.0K | 215.5K | 400.0K | 246.3K | 241.9K |
| Goodwill | - | - | - | - | - |
| Intangible Assets | - | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 349.0K | - | - | - | - |
| Total Non-Current Assets | 899.0K | 552.0K | 628.8K | 506.6K | 554.3K |
| Total Assets | 466.6M | 245.1M | 191.2M | 175.7M | 85.9M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 6.4M | 9.4M | 5.1M | 2.6M | 1.5M |
| Short-term Debt | 54.0K | 172.0K | 185.0K | 194.2K | 195.7K |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | - | - |
| Total Current Liabilities | 44.2M | 31.7M | 14.2M | 6.9M | 2.5M |
| Non-Current Liabilities | |||||
| Long-term Debt | 321.9M | 97.8M | 37.3M | 35.0M | 14.7M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | - | - | - | - | - |
| Total Non-Current Liabilities | 321.9M | 97.8M | 37.3M | 35.0M | 14.7M |
| Total Liabilities | 366.0M | 129.5M | 51.5M | 41.9M | 17.2M |
| Equity | |||||
| Common Stock | 48.0K | 37.1K | 25.5K | 21.7K | 14.9K |
| Retained Earnings | -448.9M | -271.9M | -160.1M | -96.3M | -55.9M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 100.6M | 115.6M | 139.8M | 133.8M | 68.7M |
| Key Metrics | |||||
| Total Debt | 321.9M | 98.0M | 37.4M | 35.2M | 14.9M |
| Working Capital | 421.5M | 212.8M | 176.4M | 168.3M | 82.8M |
Balance Sheet Composition
Celcuity Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -177.0M | -111.8M | -63.8M | -40.4M | -29.6M |
| Depreciation & Amortization | 167.0K | 129.9K | 142.8K | 210.9K | 303.2K |
| Stock-Based Compensation | 21.4M | 7.0M | 4.9M | 4.6M | 2.6M |
| Working Capital Changes | -6.0M | 5.1M | -1.0M | -4.4M | 1.2M |
| Operating Cash Flow | -156.7M | -96.7M | -58.7M | -39.2M | -19.9M |
| Investing Activities | |||||
| Capital Expenditures | -249.0K | -249.9K | -97.6K | -158.8K | -81.4K |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | -396.3M | -705.2M | -314.5M | -143.9M | 0 |
| Investment Sales | 332.5M | 642.3M | 309.6M | 0 | - |
| Investing Cash Flow | -64.1M | -63.1M | -5.0M | -144.0M | -81.4K |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 222.7M | 59.2M | 0 | 19.5M | 14.3M |
| Debt Repayment | - | 0 | -2.4K | -5.8K | -5.8K |
| Financing Cash Flow | 314.3M | 122.6M | 14.4M | 120.0M | 92.9M |
| Free Cash Flow | -153.5M | -83.7M | -53.9M | -36.2M | -20.4M |
| Net Change in Cash | 93.6M | -37.2M | -49.3M | -63.2M | 72.9M |
Cash Flow Trend
Celcuity Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-29.95
Forward P/E
-111.29
Price to Book
58.74
PEG Ratio
-2.12
Profitability Ratios
Profit Margin
0.00%
Operating Margin
0.00%
Return on Equity
-163.80%
Return on Assets
-30.24%
Financial Health
Current Ratio
10.55
Debt to Equity
320.13
Beta
0.42
Per Share Data
EPS (TTM)
$-3.80
Book Value per Share
$2.08
Revenue per Share
$0.00
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| CELC | 5.5B | -29.95 | 58.74 | -163.80% | 0.00% | 320.13 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Axsome Therapeutics | 9.5B | -50.54 | 105.31 | -252.12% | -28.69% | 247.03 |
| Praxis Precision | 9.6B | - | 9.46 | -45.83% | 0.00% | 0.01 |
| Bio-Techne | 9.1B | 117.16 | 4.55 | 3.80% | 6.41% | 20.07 |
Financial data is updated regularly. All figures are in the company's reporting currency.






